Elanco jumps as investors focus on upbeat 2026 outlook after strong Q4 results

Elanco Animal Health Incorporated (ELAN) is up 7.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to a renewed bullish read-through from Elanco’s latest quarterly results and initial 2026 guidance, which highlighted improving operational execution and a clearer path to margin expansion. Investors also appear to be rewarding signs that newer products are scaling and that management’s productivity program can support earnings growth and deleveraging.

Details:

Elanco reported fourth quarter and full-year 2025 results and issued initial guidance for 2026, framing expectations for revenue growth and adjusted earnings improvement.

Management highlighted cost and productivity actions, including targeted savings expected to start contributing in 2026 and build further in 2027.

Updates around the company’s innovation portfolio and newer product momentum have become a central part of the bull case, as investors try to underwrite more durable growth.

This could also be technical follow-through from recent momentum (including 52-week-high price action) after the earnings release, pulling in incremental buyers.

Sources:

Elanco Investor Relations, Nasdaq, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ELAN Insider Trading Activity

$ELAN insiders have traded $ELAN stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ELAN stock by insiders over the last 6 months:

JEFFREY N SIMMONS (PRESIDENT, CEO AND DIRECTOR) purchased 22,000 shares for an estimated $478,495
LAWRENCE ERIK KURZIUS purchased 10,000 shares for an estimated $213,000
ROBERT M VANHIMBERGEN (EVP and CFO) purchased 6,950 shares for an estimated $150,426
RAJEEV A. MODI (SEE REMARKS) purchased 4,500 shares for an estimated $95,984

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ELAN Hedge Fund Activity

We have seen 263 institutional investors add shares of $ELAN stock to their portfolio, and 218 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 14,773,349 shares (-46.9%) from their portfolio in Q4 2025, for an estimated $334,320,887
FMR LLC removed 13,161,059 shares (-20.1%) from their portfolio in Q4 2025, for an estimated $297,834,765
UBS GROUP AG removed 7,795,304 shares (-47.3%) from their portfolio in Q4 2025, for an estimated $176,407,729
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,620,713 shares (-75.2%) from their portfolio in Q4 2025, for an estimated $104,566,735
FREESTONE GROVE PARTNERS LP removed 3,841,422 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,931,379
PRIMECAP MANAGEMENT CO/CA/ removed 3,744,068 shares (-7.5%) from their portfolio in Q4 2025, for an estimated $84,728,258
INVESCO LTD. added 3,690,735 shares (+336.0%) to their portfolio in Q4 2025, for an estimated $83,521,333

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ELAN Congressional Stock Trading

Members of Congress have traded $ELAN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $ELAN stock by members of Congress over the last 6 months:

REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$ELAN Analyst Ratings

Wall Street analysts have issued reports on $ELAN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Keybanc issued a "Overweight" rating on 11/21/2025
UBS issued a "Buy" rating on 11/06/2025
JP Morgan issued a "Overweight" rating on 10/07/2025
Stifel issued a "Buy" rating on 09/24/2025

To track analyst ratings and price targets for $ELAN, check out Quiver Quantitative's $ELAN forecast page.

$ELAN Price Targets

Multiple analysts have issued price targets for $ELAN recently. We have seen 8 analysts offer price targets for $ELAN in the last 6 months, with a median target of $28.5.

Here are some recent targets:

Erin Wright from Morgan Stanley set a target price of $24.0 on 02/25/2026
Steve Dechert from Keybanc set a target price of $29.0 on 02/25/2026
Daniel Clark from Leerink Partners set a target price of $30.0 on 02/24/2026
Chris Schott from JP Morgan set a target price of $28.0 on 02/19/2026
David Westenberg from Piper Sandler set a target price of $30.0 on 01/22/2026
Glen Santangelo from Barclays set a target price of $30.0 on 12/09/2025
Andrea Alfonso from UBS set a target price of $27.0 on 11/06/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.